MiR-145 ameliorates neuropathic pain via inhibiting inflammatory responses and mTOR signaling pathway by targeting Akt3 in a rat model

2018 ◽  
Vol 134 ◽  
pp. 10-17 ◽  
Author(s):  
Jinshan Shi ◽  
Ke Jiang ◽  
Zhaoduan Li
2019 ◽  
Vol 19 (5) ◽  
pp. 622-631 ◽  
Author(s):  
Ya Liu ◽  
Jian Kang ◽  
Hong Gao ◽  
Xiyu Zhang ◽  
Jun Chao ◽  
...  

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.


Author(s):  
Liming Guo ◽  
Kuibi Tan ◽  
Qun Luo ◽  
Xu Bai

Diabetic nephropathy (DN) is the most common complication of diabetes and is prone to kidney failure. Dihydromyricetin (DHM) has been reported to have a variety of pharmacological activities. This study aims to explore the effect of DHM on DN and the underlying molecular mechanism. An in vivo DN rat model was established. The degree of renal interstitial fibrosis (RIF) was detected by hematoxylin-eosin (HE) staining, Masson's trichrome staining, and immunohistochemistry (IHC). In vitro, NRK-52E cells were divided into four groups: normal glucose (NG), high glucose (HG), HG+DHM, and HG+rapamycin (autophagy inhibitor). The levels of autophagy- and fibrosis-related proteins were analyzed by western blotting. The expression of miR-155-5p and phosphatase and tensin homolog deleted on chromosome ten (PTEN) and their relationship were assessed by quantitative reverse transcription (qRT)-PCR and dual luciferase reporter gene assay. Our results showed that RIF was increased in DN rat model and in HG-induced NRK-52E cells. DHM treatment attenuated the increased RIF and also increased autophagy. MiR-155-5p expression was increased, while PTEN expression was decreased in DN rat and cell model, and DHM reversed both effects. Dual luciferase assay showed that PTEN was the target gene of miR-155-5p. DHM inhibited HG-induced fibrosis and promoted autophagy by inhibiting miR-155-5p expression in NRK-52E cells. In addition, DHM promoted autophagy by inhibiting the PI3K/AKT/mTOR signaling pathway. In conclusion, DHM promotes autophagy and attenuates RIF by regulating the miR-155-5p/PTEN signaling and PI3K/AKT/mTOR signaling pathway in DN.


Author(s):  
Nazanin Nazari ◽  
Farzaneh Jafari ◽  
Ghasem Ghalamfarsa ◽  
Abolghasem Hadinia ◽  
Amir Atapour ◽  
...  

2021 ◽  
Author(s):  
Zhengcong Ye ◽  
Chun He ◽  
Pengzheng Yu ◽  
Guoping Cao ◽  
Qinrong Shen ◽  
...  

Abstract Background: Knee osteoarthritis (KOA) is one of the leading causes of disability, and its etiopathogenesis is not completely understood. Polydatin has the potential effect on the treatment of KOA, but the mechanism is not clear.Methods: After an KOA rat model was established by anterior cruciate ligament transection, KOA rats were treated with polydatin (4 mg/kg) for 30 days. Subsequently, cartilage tissues were collected from rats and detected by HE, TUNEL staining and Western blotting to evaluate the pathological damage, apoptosis and autophagy activity. Then, human chondrocyte C28/I2 cells were stimulated by LPS to induce a KOA model in vitro, and the effects of polydatin on the C28/I2 cell viability, apoptosis and autophagy were also detected. In addition, the mechanism of polydatin on KOA in C28/I2 cells was investigated, and the effect of an AMPK inhibitor (Dorsomorphin 2HCl) on the proliferation and apoptosis of polydatin administrated-cells were also detected. Results: After treated with polydatin, the pathological damage of rat cartilage tissues were ameliorated, cells apoptosis was inhibited and autophagy was activated in KOA rats. Meanwhile, polydatin also ameliorated the proliferation and apoptosis of C28/I2 cells, the expression of autophagy-related proteins, LC3II/LC3I, Beclin-1, and p-AMPK/AMPK were up-regulated, p-mTOR/mTOR was down-regulated by polydatin in C28/I2 cells. Interestingly, relative results showed that the improvement effect of polydatin on LPS-sdtimulated-C28/I2 cells was blocked by AMPK/mTOR inhibitor, Dorsomorphin 2HCl. Conclusion: Our research showed that polydatin reduces apoptosis and activate autophagy both in a rat model of KOA and C28/I2 cell model by AMPK/mTOR signaling pathway, which provides the basis for further investigations into the potential therapeutic impact of polydatin in KOA.


Sign in / Sign up

Export Citation Format

Share Document